Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Abstract
Focal segmental Glomerulosclerosis (FSGS) is a progressive chronic kidney disease that accounts for 4% of adults and 12% of children with end-stage kidney disease in the US. Kidney transplantation is the preferred treatment for end-stage kidney disease, however FSG can recur post-transplant in 30-50% of these patients, leading to poor graft survival. Treatment options for recurrent FSGS have included plasmapheresis or rituximab, neither of which are curative or effective in all patients. Recently, prophylactic approaches have been pursued as potential means to improve outcomes. Rituximab, an agent shown effective in the treatment of some patients with FSGS, prevented recurrence in a handful of high risk transplant patients. However, the role of pre-emptive treatment with rituximab combined with plasmapheresis in prevention of FSGS recurrence is unknown, necessitating a randomized controlled trial of this pre-transplant therapy plan.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1156598
Entities
People
- Michelle Rheault
Organizations
- University of Minnesota